Moore Amy H, Bigbee Matthew J, Boynton Grace E, Wakeham Colin M, Rosenheim Hilary M, Staral Christopher J, Morrissey James L, Hund Amanda K
Department of Biology, Carleton College, one north college street, Northfield, MN 55057, USA.
Pharmaceuticals (Basel). 2010 Jun 2;3(6):1812-1841. doi: 10.3390/ph3061812.
Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common neurodegenerative diseases with age as the greatest risk factor. As the general population experiences extended life span, preparation for the prevention and treatment of these and other age-associated neurological diseases are warranted. Since epidemiological studies suggested that non-steroidal anti-inflammatory drug (NSAID) use decreased risk for AD and PD, increasing attention has been devoted to understanding the costs and benefits of the innate neuroinflammatory response to functional recovery following pathology onset. This review will provide a general overview on the role of neuroinflammation in these neurodegenerative diseases and an update on NSAID treatment in recent experimental animal models, epidemiological analyses, and clinical trials.
阿尔茨海默病(AD)和帕金森病(PD)是最常见的神经退行性疾病,年龄是最大的风险因素。随着普通人群寿命的延长,对这些以及其他与年龄相关的神经疾病进行预防和治疗的准备工作是必要的。由于流行病学研究表明,使用非甾体抗炎药(NSAID)可降低患AD和PD的风险,因此人们越来越关注了解病理发作后先天性神经炎症反应对功能恢复的成本和益处。本综述将概述神经炎症在这些神经退行性疾病中的作用,并更新近期实验动物模型、流行病学分析和临床试验中NSAID治疗的相关情况。